It’s s301 time: here’s who’s up, and who’s down

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

It’s s301 time: here’s who’s up, and who’s down

The US government has published its annual list naming and shaming countries that it claims have failed to protect the IP rights of its citizens and companies

The US Trade Representative invites comments from IP users and owners as part of its research process: this year it says it received 42 comments from interested parties and 18 submissions from trading partners.

High on the list of concerns is what it calls “indigenous innovation” policies that may unfairly disadvantage US rights holders in China, and the continuing challenges of copyright piracy over the internet in countries such as Canada, Italy, and Russia.

On the 2012 Priority Watch List are Algeria, Argentina, Canada, Chile, China, India, Indonesia, Israel, Pakistan, Russia, Thailand, Ukraine and Venezuela.

But it highlights a number of countries for praise: copyright reforms in Malaysia that increase the role of ISPs in tackling online infringement and preventing the circumvention of technological protection measures are lauded, as is Israel’s decision to enact a law against the unfair commercial use and unauthorised disclosure of test data generated to obtain marketing approval of pharmaceutical products.

China is also praised for putting Vice-Premier Wang Qishan in charge of overseeing IP enforcement.

But the country is criticised for failing to implement a consistent policy for tackling counterfeiting, with different regions imposing their own regimes, and in some cases demonstrating local protectionism.

India is told that the US will “closely monitor” developments relating to the compulsory licensing of patents after the country’s Controller of Patents granted local company Natco a compulsory licence over Bayer’s cancer-treating drug sorafenib.

This year’s report emphasises how the US is working with countries that appear on its list. No longer does it just highlight their sub-optimal IP practices: now it helps them to reform.

“[We] conduct extensive discussions with individual trading partners regarding their respective IPR regimes; encourage those trading partners to engage fully, and with the greatest degree of transparency, with the range of stakeholders on IPR matters; and identify, where possible, ways in which the United States can be of assistance.”

more from across site and SHARED ros bottom lb

More from across our site

Erise IP has added a seven-practitioner trademark team from Hovey Williams, signalling its intention to help clients at all stages of development
News of prison sentences for ex-Samsung executives for trade secrets violation and an opposition filed by Taylor Swift were also among the top talking points
A multijurisdictional claim filed by InterDigital and a new spin-off firm in Germany were also among the top talking points
Duarte Lima, MD of Spruson & Ferguson’s Asia practice, says practitioners must adapt to process changes within IP systems, as well as be mindful of the implications of tech on their practices
Practitioners say the UK Supreme Court’s decision could boost the attractiveness of the UK for AI companies
New awards, including US ‘Firm of the Year’ and Latin America ‘Firm to Watch’, are among more than 90 prizes that will recognise firms and practitioners
DWF helped client Dairy UK secure a major victory at the UK Supreme Court
Hepworth Browne led Emotional Perception AI to victory at the UK Supreme Court, which rejected a previous appellate decision that said an AI network was not patentable
James Hill, general counsel at Norwich City FC, reveals how he balances fan engagement with brand enforcement, and when he calls on IP firms for advice
In the second of a two-part article, Gabrielle Faure-André and Stéphanie Garçon at Santarelli unpick EPO, UPC and French case law to assess the importance of clinical development timelines in inventive step analyses
Gift this article